银诺医药-B(02591.HK)：已在中国完成核心产品用于治疗肥胖和超重的III期临床试验的首例患者给药

Core Insights - The company, Silver诺医药-B (02591.HK), has initiated a Phase IIb/III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight in China, set to start in March 2025 [1] - As of September 30, 2025, the company has administered the first dose to a patient in the Phase III clinical trial for the treatment of obesity and overweight in China [1] - The company plans to recruit approximately 800 participants for this clinical trial [1]